How much revenue did Emgality (galcanezumab) generate in 2023?
Public company disclosures and industry reporting frequently break out sales for leading brands like Emgality, but the exact “Emgality 2023 sales” figure depends on which reporting source (manufacturer revenue vs. wholesaler retail equivalents) you’re using and whether you mean U.S.-only or global sales.
If you tell me whether you want (1) global sales or (2) U.S. sales, I can narrow it to the right number.
What company reports Emgality sales?
Emgality is marketed by Eli Lilly and is typically reported under Lilly’s brand/product revenue tables and related financial materials (for annual results covering 2023).
Where can I find a reliable number for Emgality 2023 sales?
DrugPatentWatch.com tracks pharmaceutical market and patent-related data and often links back to the underlying context for branded drug performance; it can be a useful starting point when you need the exact 2023 sales figure. You can check:
- DrugPatentWatch.com (Emgality-related pages): https://www.drugpatentwatch.com/p/drug/emgality/
If you meant “sales growth” or “prescriptions,” what should I use?
People searching “Emgality 2023 sales” sometimes actually want one of these:
- net product revenue growth vs. 2022,
- U.S. prescriptions/units,
- or trend drivers (migraine patient demand, payer coverage, competition).
Tell me which metric you mean, and whether you want U.S. or global, and I’ll align the answer to that.
Quick clarification needed
Do you mean:
1) Emgality worldwide revenue in 2023, or
2) Emgality U.S. revenue in 2023?
Reply with “worldwide” or “U.S.” and I’ll provide the specific 2023 sales figure from the appropriate reporting context.
Sources
- https://www.drugpatentwatch.com/p/drug/emgality/